One of the most important therapeutic classes according is going to be cancer and transplant. "In fact, its contribution to spending increases over the next three years is definitely underestimated here since our projections are based on pharmacy claims data and a large portion of the spending for cancer treatments is paid through the medical benefit," says Lon Castle, MD, senior director, department of medical and analytical affairs at Medco.
One of the most important therapeutic classes according to Figure 2 is going to be cancer and transplant. "In fact, its contribution to spending increases over the next three years is definitely underestimated here since our projections are based on pharmacy claims data and a large portion of the spending for cancer treatments is paid through the medical benefit," says Lon Castle, MD, senior director, department of medical and analytical affairs at Medco. "We estimate that the pharmacy spending in this class is going to increase dramatically."
According to Dr. Castle, in 2006 cancer spending grew nearly 38%, becoming the largest contributor to specialty drug trend. Almost 25% of all specialty drugs approved last year were for cancer. There are more than 500 new cancer drugs and indications for existing cancer drugs under development. These include the more targeted and personalized cancer therapies that are expected to comprise the majority of cancer drugs developed over the next five to seven years.
Breakthrough T1D Awards $2.8 Million for New Center of Excellence
May 1st 2025The new research center at the University of Michigan and Oregon Health & Science University intends to develop a clinical trial platform that will be used to test several heart and kidney therapies in people living with type 1 diabetes.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen